ArticleFrontiers in oncology2026
Integrating network pharmacology, molecular docking, and experimental validation, this study explores the mechanism of action of Typhonii Rhizoma in colon cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Typhonii Rhizoma (TR), the dried tuber of Methods: This study employed a comprehensive approach combining network pharmacology, molecular docking, and experimental validation to elucidate the potential anticancer mechanism of TR against colon cancer. Initially, the targets of TR and colon cancer were retrieved from public databases, and their intersection targets were identified. Subsequently, these targets were subjected to protein-protein interaction (PPI) network analysis, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses to identify key pathways. Molecular docking was then performed to evaluate potential interactions between active TR components and core targets. Finally, the predicted mechanisms were validated through a series of Results: Network pharmacology analysis identified 101 intersection targets shared by TR and colon cancer, with the PI3K/AKT signaling pathway emerging as the core pathway mediating the anti-colon cancer effects of TR. Furthermore, molecular docking suggested favorable interactions between several candidate components of TR and AKT1/PI3K. Consistent with these predictions, Discussion: These findings suggest that TR inhibits malignant phenotypes of colon cancer cells and may be associated with modulation of the PI3K/AKT pathway
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.